Publications

European journal of pharmacology

Taxanes: old drugs, new oral formulations.

05-10-2013

Cancer treatment reviews

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.

01-10-2013

Pharmacological research

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

01-10-2013

Investigational new drugs

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

01-10-2013

Rapid communications in mass spectrometry : RCM

Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry.

15-09-2013

International journal of pharmaceutics

Long term stability of lyophilized plasmid DNA pDERMATT.

10-09-2013

International journal of cancer

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

01-09-2013

Gynecologic oncology

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

01-09-2013

The Journal of pharmacology and experimental therapeutics

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.

01-09-2013

British journal of clinical pharmacology

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

01-09-2013

Journal of clinical pharmacology

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

01-08-2013

Vaccine

Transposon leads to contamination of clinical pDNA vaccine.

11-07-2013

British journal of clinical pharmacology

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

01-07-2013

Cancer treatment reviews

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

01-06-2013

Clinical pharmacokinetics

Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

01-06-2013

Drug delivery and translational research

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

01-06-2013

The oncologist

Concise drug review: azacitidine and decitabine.

15-05-2013

International journal of cancer

P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.

15-05-2013

Nederlands tijdschrift voor geneeskunde

[Concomitant use of proton pump inhibitors and systemic corticosteroids].

10-05-2013

CNS oncology

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

01-05-2013

European journal of cancer (Oxford, England : 1990)

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

01-05-2013

Clinical cancer research : an official journal of the American Association for Cancer Research

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

15-04-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.

15-04-2013

Investigational new drugs

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.

01-04-2013

Therapeutic drug monitoring

Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.

01-04-2013

Biomedical chromatography : BMC

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

01-04-2013

International journal of radiation oncology, biology, physics

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

01-04-2013

Drugs in R&D

Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.

01-03-2013

Analytical and bioanalytical chemistry

Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells.

01-03-2013

Analytical and bioanalytical chemistry

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination.

01-03-2013

British journal of clinical pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

01-02-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

15-01-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

15-01-2013

Cancer chemotherapy and pharmacology

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

01-01-2013

Therapeutic advances in medical oncology

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

01-01-2013

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

01-01-2013

Pharmaceutical research

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

01-12-2012

Cancer chemotherapy and pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

01-12-2012

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

01-12-2012

BMJ (Clinical research ed.)

Commentary: Substandard medicines are the priority for neglected tropical diseases.

14-11-2012

Molecular pharmaceutics

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

05-11-2012

Cancer chemotherapy and pharmacology

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.

01-11-2012

Bioanalysis

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

01-11-2012

Molecular pharmaceutics

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

04-09-2012

The AAPS journal

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

01-09-2012

Cytometry. Part A : the journal of the International Society for Analytical Cytology

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.

01-08-2012

Investigational new drugs

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

01-08-2012

British journal of clinical pharmacology

Model-based treatment optimization of a novel VEGFR inhibitor.

01-08-2012

Investigational new drugs

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

01-08-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

15-07-2012

Taxanes: old drugs, new oral formulations.

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry.

Long term stability of lyophilized plasmid DNA pDERMATT.

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

Transposon leads to contamination of clinical pDNA vaccine.

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

Concise drug review: azacitidine and decitabine.

P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.

[Concomitant use of proton pump inhibitors and systemic corticosteroids].

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.

Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.

Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.

Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells.

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

Commentary: Substandard medicines are the priority for neglected tropical diseases.

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

Model-based treatment optimization of a novel VEGFR inhibitor.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

This site uses cookies